300 related articles for article (PubMed ID: 29736895)
1. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.
McQueen RB; Sheehan DN; Whittington MD; van Boven JFM; Campbell JD
Pharmacoeconomics; 2018 Aug; 36(8):957-971. PubMed ID: 29736895
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
Faria R; McKenna C; Palmer S
Value Health; 2014 Dec; 17(8):772-82. PubMed ID: 25498772
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.
Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
Pharmacoeconomics; 2018 Oct; 36(10):1165-1200. PubMed ID: 29869050
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
[TBL] [Abstract][Full Text] [Related]
6. Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?
Kim CH; Dilokthornsakul P; Campbell JD; van Boven JFM
J Allergy Clin Immunol Pract; 2018; 6(2):619-632. PubMed ID: 28967548
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of asthma therapy: a comprehensive review.
Domínguez-Ortega J; Phillips-Anglés E; Barranco P; Quirce S
J Asthma; 2015; 52(6):529-37. PubMed ID: 25539023
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
Brown R; Turk F; Dale P; Bousquet J
Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.
Zhou H; Lu Y; Wu B; Che D
J Asthma; 2020 Jan; 57(1):87-94. PubMed ID: 30507328
[No Abstract] [Full Text] [Related]
10. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
Sullivan SD; Turk F
Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
[TBL] [Abstract][Full Text] [Related]
11. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain.
Vennera Mdel C; Valero A; Uría E; Forné C; Picado C
Clin Drug Investig; 2016 Jul; 36(7):567-78. PubMed ID: 27142072
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence.
Igarashi A; Kaur H; Choubey A; Popli A; Muthukumar M; Yoshisue H; Funakubo M; Ohta K
Value Health Reg Issues; 2022; 27():41-48. PubMed ID: 34784547
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.
Ehteshami-Afshar S; Zafari Z; Hamidi N; FitzGerald JM; Lynd L; Sadatsafavi M
Value Health; 2019 Sep; 22(9):1070-1082. PubMed ID: 31511184
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice.
Martínez-Moragón E; Climent M; Chiner E; Fernández-Aracil C; Sánchez-Toril F; Lluch-Tortajada I
Farm Hosp; 2019 May; 43(3):101-109. PubMed ID: 31072288
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic review of medical management of persistent asthma.
Cheng JW; Arnold RJ
Allergy Asthma Proc; 2008; 29(2):109-22. PubMed ID: 18430307
[TBL] [Abstract][Full Text] [Related]
18. Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review.
Chongmelaxme B; Chaiyakunapruk N; Dilokthornsakul P
J Med Econ; 2019 Jun; 22(6):554-566. PubMed ID: 30663455
[No Abstract] [Full Text] [Related]
19. Anti-immunoglobulin E therapy with omalizumab for asthma.
Hendeles L; Sorkness CA
Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
